Answers are grounded in this paper and cite their sources.
Autologous vein is the preferred conduit for infrainguinal bypass, but a suitable vein is not always available. Cadaveric venous homografts offer an alternative, although their long-term outcomes remain uncertain. This systematic review assessed long-term outcomes after infrainguinal homograft bypass and used the available evidence to develop the exploratory HOPE (Homograft Outcome and Prognostic Evidence) Framework. We searched PubMed, Embase and CENTRAL for studies of adults undergoing infrainguinal bypass using cadaveric venous homografts, with the final search conducted on 15 September 2026. Eligible studies reported at least one outcome at three years or later. Outcomes of interest included graft patency, limb salvage, freedom from major amputation, major amputation and survival. Study quality was assessed using the Joanna Briggs Institute Critical Appraisal Checklist for Cohort Studies. Graft-volume-weighted patency estimates were calculated descriptively, and reported outcome associations informed development of the exploratory HOPE Framework. Ten studies were included. Weighted primary or overall patency was 52.8% at 1 year (8 studies; 848 grafts), 33.3% at 3 years (6 studies; 533 grafts), and 26.5% at 5 years (5 studies; 628 grafts). Secondary patency was 58.8% at 1 year (5 studies; 566 grafts), 50.6% at 3 years (3 studies; 251 grafts), and 37.4% at 5 years (3 studies; 426 grafts). Limb and other clinical outcomes varied between studies and were therefore reported separately. Four factors were included in HOPE: surgical context, distal target, severe renal disease, particularly end-stage renal disease, and graft configuration. We did not include preservation method because its relationship with long-term outcomes was inconsistent. HOPE does not use numerical weights, risk groups, or individual outcome estimates. Cadaveric venous homografts remain an option when suitable autologous vein is unavailable, although long-term patency is limited. HOPE provides an exploratory, evidence-informed framework for considering factors associated with long-term homograft outcomes rather than predicting individual outcomes. Prospective multicentre studies using standardised patient-level data are needed to test these factors and determine whether they could support a reliable prediction model. Interpretation is limited by heterogeneous observational studies, inconsistent outcome definitions and incomplete long-term follow-up reporting. Open Science Framework (OSF), DOI: https://doi.org/10.17605/OSF.IO/53TNC .
No takes yet. Share an insight, caveat, or question.
Dhahri et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: